Medicare Fee Schedule: Implications for Biologics Compliance
Applied Biologics, headquartered in Scottsdale, Arizona, has emphasized a significant aspect of the Centers for Medicare & Medicaid Services' (CMS) proposed rule for the 2027 Medicare Physician Fee Schedule. The rule recognizes the distinct regulatory compliance requirements for FDA-licensed biologics developed under Section 351 of the Public Health Service Act. This acknowledgment underscores the rigorous scientific and manufacturing standards necessary for biologic therapies targeting serious diseases.
The company's flagship investigational product, BIOxHEAL™, is designed to treat chronic wounds and is being developed under the stringent regulatory pathway of Section 351. Although BIOxHEAL has not yet received FDA approval, the product's safety and efficacy remain under careful evaluation as part of its clinical validation process.
Edward Britt, CEO of Applied Biologics, emphasized the company's dedication to meeting the high standards set for biologic therapies. He highlighted the considerable investment in quality manufacturing, analytical procedures, and clinical testing to comply with regulatory frameworks, which he views as beneficial for healthcare providers and patients alike. Britt reaffirmed the company's focus on rigorous scientific and clinical processes to drive innovation, with BIOxHEAL advancing through Phase 3 clinical trials and an expanding pipeline that includes treatments for degenerative diseases and regenerative medicine.
The company stresses the importance of alignment between FDA and Medicare policies in maintaining robust scientific and clinical foundations in advanced wound care. Applied Biologics is committed to research and development characterized by scientific precision and the pursuit of regulatory approval for its investigational therapies. However, they acknowledge that forward-looking statements in their press release regarding potential Medicare policy changes and regulatory progress are subject to uncertainties.